Shanghai Junshi Biosciences Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Shanghai Junshi Biosciences Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 14 Jul 2020 | Lorem |
| Shanghai Junshi plans pivotal PD-1 Tuoyi studies by YE19/early 2020, Phase I anti-BTLA study in three months, exec says | 21 May 2019 | Manasi Vaidya |
| China drug in-licensing opportunities expected to swell as local pharma focus on R&D, following venture financing and public listing upsurge, experts say | 29 Apr 2019 | Shuan Sim,Manasi Vaidya |
| Chinese checkpoint inhibitors’ cost advantage provides initial edge over Merck, BMS approvals in China; other factors will influence long-term market share, experts say | 26 Apr 2019 | Manasi Vaidya,Shuan Sim |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer